Preparative Haemapheresis and Donor Safety
The need of blood components has increased continuously within the last decades. While in the USA the number of transfused RBCs nearly doubled from 6.3 to 12.4 millions between 1971 and 1999, the usage of platelets increased 22-fold from 0.4 to 9.1 units within this period [1] . Thus, the percentage of platelet concentrates increased from 5 to 37% of the total blood use while the percentage of RBCs decreased from 92 to 50%. There are no data documenting this development for Germany or the European Union. However there are two investigations on blood use in Germany published by the Paul-Ehrlich-Institut for 1998 [2] as well as for 1999 to 2000 [3] and two investigations from the University Hospital Erlangen [4, 5] which should be representative for the utilisation of blood components in hospitals of maximum medical care. These data show that in Germany the percentage of platelet concentrates rose continuously from 22% of the total utilisation of blood components in 1998 to 26% in 2000 [3] . Depending on the clinical department, platelet concentrates represent 25-56% of the total utilisation of blood components in the university hospital [4, 5] . On the one hand there is an increasing need for blood components, specifically platelet concentrates, and on the other hand a decrease of the number of available blood donors, which is caused by a decreasing willingness for blood donation and by donor exclusion criteria becoming more and more stringent [6] . The resulting increase of the number of donations per donor forces us to critically analyse the potential risks for a donor caused by whole blood or apheresis donation. This analysis is supported by a review given by Popovsky in this issue of TRANSFUSION MEDICINE AND HEMOTHERAPY [7] . Popovsky demonstrates that whole blood donation as well as apheresis donations may bear serious risks for donors. This applies particularly for events such as haematoma, arterial puncture, nerve injury and vasovagal reaction caused by the phlebotomy. Such events less frequently occur during apheresis donation than during whole blood donation [8, 9] . Data from 1997 to 1999 compiled by the DGTI-section 'Preparative and Therapeutical Haemapheresis' demonstrate that the incidence of vasovagal reactions during plateletapheresis is 0.1-0.3% [10] . However citrate toxicity is an event that only occurs during apheresis donation, requiring a very careful donor selection and care. As shown by Laspina et al. [11] , citrate caused changes of the donors' electrocardiogram (ECG) during apheresis. It is therefore recommended to identify all donors carrying cardiological risk factors before the first donation. Despite the costs of the additional examination, this selection procedure should be based not only on the medical history but also on an additional ECG examination because it was shown by Glaser et al. [6] that, even in a group of 770 donors without detectable anamnestic risk factors, pathological changes of the ECG occurred in 1,7% of the donors. Describing RBC apheresis, Popowsky points to a new issue opened by multi-component donation. However the term 'multi-component donation' is not clearly specified so far. It is used either for donation procedures leading to at least 2 different products (e.g. 1 unit of RBCs and 1 unit of platelets) or for all procedures leading to more than one product (e.g. 2 units of RBCs or 2 units of platelets). Thus, the term requires a standardised definition. The intensified use of donation procedures in which more than one blood product is collected bears new potential risks for the donors. Obviously, the iron loss is significantly higher when collecting 2 units of RBCs instead of 1 unit [12, 13] . Even if RBCs regenerated completely after 2 months, the donors's ferritin levels remained reduced for 4 months [12, 13] . Thus it has to be concluded that the withdrawal of 2 units of RBCs influences the donors' iron metabolism, necessitating an intensive monitoring of these donors. Long-term decreased ferritin levels and increased erythropoietin and transferrin lev- Editorial els after one single collection of 2 units of RBCs are other indicators for modifications of the donors' metabolism. Moreover, it was shown by Dettke et al. [14] that citrate effects the bone metabolism in plateletapheresis donors. Using apheresis techniques, increasing numbers of blood components can be collected in spite of a decreasing donor population [15] . This results in a higher number of collected components per donor and a potentially higher likelihood for the individual donor to experience adverse effects during or after the donation. This and especially possible long-term adverse effects requires our attendance. The German and European Guidelines [16, 17] however focus much more on the recipients' than on the donors' safety so far. This might be caused by the scarce data, especially with respect to long-term adverse effects of multi-component donations. New definitions of donor selection criteria, donor safety controls as well as donation intervals are needed for the different blood component combinations to be collected. The scientific associations are obliged to perform a survey of current data on long-term tolerance of multi-component donation for updating the existing recommendations for preparative cytapheresis [18] .
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